Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors

Yekeduz E., UTKAN G., ÜRÜN Y.

FUTURE ONCOLOGY, cilt.18, ss.413-416, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 18
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fon-2021-1513
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.413-416
  • Anahtar Kelimeler: cancer, HIV, immunotherapy, HEPATITIS, RESERVOIR, LYMPHOMA
  • Ankara Üniversitesi Adresli: Evet

Özet

HIV-infected patients are more susceptible to cancer due to their immune-compromised condition and HIV infection. Chronic inflammation and immune dysregulation are the main causes of cancer development in these patients. Because of lymphopenia and an immune-compromised condition, most HIV-infected patients with cancer were not considered for cytotoxic therapies, such as chemotherapy and radiotherapy. Immune checkpoint inhibitors (ICIs) have become a game-changer in many cancer types. However, not enough prospective data is available regarding the use of ICIs in HIV-infected patients with cancer. Retrospective data from case reports/series showed that ICIs are safe in HIV-infected patients with cancer.